{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:16:35Z","timestamp":1792793795758,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"The National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2024-00441029"],"award-info":[{"award-number":["RS-2024-00441029"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43347-5","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:23:13Z","timestamp":1772990593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Statin use and the risk of liver-related events in older adults with steatotic liver disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Eun Seok","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-8998","authenticated-orcid":false,"given":"Seogsong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7498-4829","authenticated-orcid":false,"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"1","key":"43347_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11883-024-01265-9","volume":"27","author":"RD Paparodis","year":"2024","unstructured":"Paparodis, R. D., Bantouna, D., Livadas, S. & Angelopoulos, N. Statin therapy in primary and secondary cardiovascular disease prevention. Curr. Atheroscler Rep. 27 (1), 21 (2024).","journal-title":"Curr. Atheroscler Rep."},{"key":"43347_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies","year":"2019","unstructured":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 290, 140\u2013205 (2019).","journal-title":"Atherosclerosis"},{"key":"43347_CR3","doi-asserted-by":"crossref","unstructured":"Grundy, S. M., Stone, N. J., Bailey, A. L., NLA\/PCNA Guideline on the management of blood cholesterol. & et al a report of the american college of cardiology\/American heart association task force on clinical practice guidelines. circulation 139 (25), e1082\u2013e1143 (2019). 2018 .","DOI":"10.1161\/CIR.0000000000000698"},{"issue":"6","key":"43347_CR4","doi-asserted-by":"publisher","first-page":"e2320222","DOI":"10.1001\/jamanetworkopen.2023.20222","volume":"6","author":"MS Vell","year":"2023","unstructured":"Vell, M. S. et al. Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality. JAMA Netw. Open. 6 (6), e2320222 (2023).","journal-title":"JAMA Netw. Open."},{"issue":"19","key":"43347_CR5","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1001\/jama.2016.15212","volume":"316","author":"JH Gurwitz","year":"2016","unstructured":"Gurwitz, J. H., Go, A. S. & Fortmann, S. P. Statins for primary prevention in older adults: uncertainty and the need for more evidence. JAMA 316 (19), 1971\u20131972 (2016).","journal-title":"JAMA"},{"key":"43347_CR6","doi-asserted-by":"publisher","first-page":"k3695","DOI":"10.1136\/bmj.k3695","volume":"362","author":"A Ryan","year":"2018","unstructured":"Ryan, A., Heath, S. & Cook, P. Primary prevention with statins for older adults. BMJ 362, k3695 (2018).","journal-title":"BMJ"},{"issue":"7","key":"43347_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s43587-024-00652-w","volume":"4","author":"K Du","year":"2024","unstructured":"Du, K. et al. Aging promotes metabolic dysfunction-associated steatotic liver disease by inducing ferroptotic stress. Nat. Aging. 4 (7), 949\u2013968 (2024).","journal-title":"Nat. Aging"},{"issue":"1","key":"43347_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2217\/pgs-2023-0199","volume":"25","author":"S Abudahab","year":"2024","unstructured":"Abudahab, S., Slattum, P. W., Price, E. T. & McClay, J. L. Epigenetic regulation of drug metabolism in aging: utilizing epigenetics to optimize geriatric pharmacotherapy. Pharmacogenomics 25 (1), 41\u201354 (2024).","journal-title":"Pharmacogenomics"},{"issue":"6","key":"43347_CR9","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79 (6), 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"issue":"6","key":"43347_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.31083\/j.rcm2406173","volume":"24","author":"Y Lim","year":"2023","unstructured":"Lim, Y., Jeong, S., Hong, M. & Han, H. W. Non-alcoholic fatty liver disease, atherosclerosis, and cardiovascular disease in Asia. Rev. Cardiovasc. Med. 24 (6), 173 (2023).","journal-title":"Rev. Cardiovasc. Med."},{"issue":"4","key":"43347_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5009\/gnl210256","volume":"16","author":"S Jeong","year":"2022","unstructured":"Jeong, S. et al. Metabolic dysfunction-associated fatty liver disease better predicts incident cardiovascular disease. Gut Liver. 16 (4), 589\u2013598 (2022).","journal-title":"Gut Liver"},{"issue":"1","key":"43347_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12876-025-03814-1","volume":"25","author":"WY Shin","year":"2025","unstructured":"Shin, W. Y. et al. Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study: MASLD, MetALD, and dementia risk. BMC Gastroenterol. 25 (1), 308 (2025).","journal-title":"BMC Gastroenterol."},{"issue":"3","key":"43347_CR13","doi-asserted-by":"publisher","first-page":"e70156","DOI":"10.1002\/lio2.70156","volume":"10","author":"ES Kang","year":"2025","unstructured":"Kang, E. S. et al. Association of metabolic dysfunction-associated steatotic liver disease with sudden sensorineural hearing loss among older adults. Laryngoscope Investig Otolaryngol. 10 (3), e70156 (2025).","journal-title":"Laryngoscope Investig Otolaryngol."},{"issue":"3","key":"43347_CR14","first-page":"799","volume":"46","author":"S Cheol Seong","year":"2017","unstructured":"Cheol Seong, S. et al. Data resource profile: the national health information database of the national health insurance service in South Korea. Int. J. Epidemiol. 46 (3), 799\u2013800 (2017).","journal-title":"Int. J. Epidemiol."},{"issue":"4","key":"43347_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1159\/000535943","volume":"13","author":"GA Kim","year":"2023","unstructured":"Kim, G. A. et al. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatotic liver disease with increased alcohol intake increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis: A Korean nationwide study. Liver Cancer. 13 (4), 426\u2013437 (2023).","journal-title":"Liver Cancer"},{"issue":"1","key":"43347_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hep.28506","volume":"64","author":"TG Simon","year":"2016","unstructured":"Simon, T. G., Bonilla, H., Yan, P., Chung, R. T. & Butt, A. A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology 64 (1), 47\u201357 (2016).","journal-title":"Hepatology"},{"issue":"25","key":"43347_CR17","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1161\/CIR.0000000000000624","volume":"139","author":"S. M. Grundy","year":"2019","unstructured":"Grundy, S. M. et al. NLA\/PCNA guideline on the management of blood cholesterol. & executive summary: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. Circulation 139 (25), e1046\u2013e1081 (2019).","journal-title":"Circulation"},{"key":"43347_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni, G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33 (2006).","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"43347_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13098-022-00811-2","volume":"14","author":"AL Han","year":"2022","unstructured":"Han, A. L. Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease. Diabetol. Metab. Syndr. 14 (1), 44 (2022).","journal-title":"Diabetol. Metab. Syndr."},{"issue":"2","key":"43347_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7570\/jomes22024","volume":"31","author":"YS Yang","year":"2022","unstructured":"Yang, Y. S. et al. Obesity Fact Sheet in Korea, 2021: Trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J. Obes. Metab. Syndr. 31 (2), 169\u2013177 (2022).","journal-title":"J. Obes. Metab. Syndr."},{"issue":"3","key":"43347_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL). European association for the study of diabetes (EASD); European association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81 (3), 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"issue":"446","key":"43347_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A Proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94 (446), 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"issue":"1","key":"43347_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","volume":"116","author":"JI Lee","year":"2021","unstructured":"Lee, J. I., Lee, H. W., Lee, K. S., Lee, H. S. & Park, J. Y. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Am. J. Gastroenterol. 116 (1), 116\u2013124 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"43347_CR24","doi-asserted-by":"publisher","first-page":"115644","DOI":"10.1016\/j.bcp.2023.115644","volume":"214","author":"DM Dolivo","year":"2023","unstructured":"Dolivo, D. M. et al. Anti-fibrotic effects of statin drugs: A review of evidence and mechanisms. Biochem. Pharmacol. 214, 115644 (2023).","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"43347_CR25","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","volume":"64","author":"G Marrone","year":"2015","unstructured":"Marrone, G. et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 64 (9), 1434\u20131443 (2015).","journal-title":"Gut"},{"issue":"4","key":"43347_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","volume":"53","author":"J Trebicka","year":"2010","unstructured":"Trebicka, J. et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Hepatol. 53 (4), 702\u2013712 (2010).","journal-title":"J. Hepatol."},{"issue":"6","key":"43347_CR27","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00204-023-03492-6","volume":"97","author":"CA German","year":"2023","unstructured":"German, C. A. & Liao, J. K. Understanding the molecular mechanisms of statin pleiotropic effects. Arch. Toxicol. 97 (6), 1529\u20131545 (2023).","journal-title":"Arch. Toxicol."},{"issue":"2","key":"43347_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/pharmaceutics16020214","volume":"16","author":"N Khatiwada","year":"2024","unstructured":"Khatiwada, N. & Hong, Z. Potential benefits and risks associated with the use of statins. Pharmaceutics 16 (2), 214 (2024).","journal-title":"Pharmaceutics"},{"issue":"2","key":"43347_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jhep.2020.08.033","volume":"74","author":"M Winkler","year":"2021","unstructured":"Winkler, M. et al. Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling. J. Hepatol. 74 (2), 380\u2013393 (2021).","journal-title":"J. Hepatol."},{"issue":"11","key":"43347_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00018-023-04966-7","volume":"80","author":"RI Velliou","year":"2023","unstructured":"Velliou, R. I., Legaki, A. I., Nikolakopoulou, P., Vlachogiannis, N. I. & Chatzigeorgiou, A. Liver endothelial cells in NAFLD and transition to NASH and HCC. Cell. Mol. Life Sci. 80 (11), 314 (2023).","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"43347_CR31","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2174\/1568009623666230418121130","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. The role of oxidative stress in the development and therapeutic intervention of hepatocellular carcinoma. Curr. Cancer Drug Targets. 23 (10), 792\u2013804 (2023).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"3","key":"43347_CR32","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","volume":"79","author":"BP Lee","year":"2024","unstructured":"Lee, B. P., Dodge, J. L. & Terrault, N. A. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology 79 (3), 666\u2013673 (2024).","journal-title":"Hepatology"},{"issue":"6","key":"43347_CR33","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","volume":"22","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros, M. et al. Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017\u20132020. Clin. Gastroenterol. Hepatol. 22 (6), 1330\u20131332e4 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"43347_CR34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.rce.2023.04.003","volume":"223","author":"I Cusacovich","year":"2023","unstructured":"Cusacovich, I. et al. Prevalence of nonalcoholic fatty liver disease in a Spanish town: a population-based study. Rev. Clin. Esp. (Barc). 223 (7), 396\u2013404 (2023).","journal-title":"Rev. Clin. Esp. (Barc)"},{"issue":"7","key":"43347_CR35","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/ajg.2016.179","volume":"111","author":"YW Huang","year":"2016","unstructured":"Huang, Y. W. et al. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. Am. J. Gastroenterol. 111 (7), 976\u2013985 (2016).","journal-title":"Am. J. Gastroenterol."},{"issue":"11","key":"43347_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","volume":"73","author":"XD Zhou","year":"2024","unstructured":"Zhou, X. D. et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut 73 (11), 1883\u20131892 (2024).","journal-title":"Gut"},{"issue":"Suppl 2","key":"43347_CR37","doi-asserted-by":"publisher","first-page":"S325","DOI":"10.2337\/dcS13-2038","volume":"36","author":"R Bitzur","year":"2013","unstructured":"Bitzur, R., Cohen, H., Kamari, Y. & Harats, D. Intolerance to statins: mechanisms and management. Diabetes Care. 36 (Suppl 2), S325\u2013S330 (2013).","journal-title":"Diabetes Care"},{"issue":"2","key":"43347_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","volume":"124","author":"NC Ward","year":"2019","unstructured":"Ward, N. C., Watts, G. F. & Eckel, R. H. Statin toxicity. Circ. Res. 124 (2), 328\u2013350 (2019).","journal-title":"Circ. Res."},{"issue":"1","key":"43347_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","volume":"70","author":"E Pose","year":"2019","unstructured":"Pose, E., Trebicka, J., Mookerjee, R. P., Angeli, P. & Gin\u00e8s, P. Statins: Old drugs as new therapy for liver diseases? J. Hepatol. 70 (1), 194\u2013202 (2019).","journal-title":"J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43347-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43347-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43347-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:00:06Z","timestamp":1776380406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43347-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43347"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43347-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12615"}}